

**AKUMS**  
**DRUGS & PHARMACEUTICALS LTD.**



Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,  
(Adjoining CBSE Office) Delhi - 110083 (INDIA).

+91-11-69041000

CIN: L24239DL2004PLC125888

www.akums.in

akumsho@akums.net

+91-11-27023256

Ref: Akums/Exchange/2025-26/57

November 13, 2025

**To,**  
**The Listing Department**  
**National Stock Exchange of India Ltd**  
**Exchange Plaza, C-1, Block G,**  
**Bandra Kurla Complex,**  
**Bandra (E), Mumbai - 400 051**

**Symbol: AKUMS**

**To,**  
**The Listing Department**  
**BSE Limited**  
**Rotunda Building, Phiroze Jeejeebhoy**  
**Towers, Dalal Street, Fort, Mumbai -**  
**400 001**

**Scrip Code: 544222**

**Sub: Press Release**

Respected Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of press release is enclosed herewith.

This is for your kind information and record.

Thanking You

**For Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik  
Company Secretary & Compliance Officer

Encl: as above

Registered Office

304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).

+91-11-47511000

+91-11-27023256

# Akums Reports Q2 FY26 Results; Strengthens International Presence

New Delhi, November 2025:

Akums Drugs & Pharmaceuticals Ltd., India's Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the second quarter of FY26.

The CDMO segment remained the key contributor with revenue of ₹804 crore. Volumes for the CDMO vertical grew 7% y-o-y, as against muted industry volume growth, reflecting Akums' position as preferred CMDO partner in India. The domestic Branded Formulations business recorded revenue of ₹122 crore, with EBITDA margins improving to 21.6%, supported by focused portfolio management. The Branded Export segment, although had seasonal impact from various countries, maintained healthy EBITDA margin of 24.5%,

For the quarter ended September 30, 2025, Akums reported consolidated revenue of ₹1,018 crore compared to ₹1,024 crore in Q1 FY26 and ₹1,033 crore in Q2 FY25. The EBITDA stood at ₹94 crore with a margin of 9.3%. The PAT was ₹43 crore. For the first half of FY26, revenue stood at ₹2,042 crore with an EBITDA of ₹223 crore (margin of 10.9%) and PAT of ₹107 crore.

The Hon'ble President of Zambia recently did ground breaking of the pharmaceutical plant, set up as a joint venture between Akums and the Govt. of The Republic of Zambia. This marks a significant step in expanding Akums' global reach. The Zambian facility is aimed at supporting access to quality medicines across the SADC Countries, with product range across multiple therapeutic areas and dosage forms.

Another milestone Akums achieved recently was the first commercial supply of formulations in Europe, with the supply of Dapagliflozin tablets to Switzerland. Akums will also supply Rivaroxaban tablets in Europe in Q3. The European contract for oral liquid supply is on track with Plant 2 undergoing EU-GMP Audit in October.

Commenting on the quarterly performance, Mr. Sanjeev Jain, Managing Director, Akums Drugs & Pharmaceuticals Ltd., said: *"Our performance this quarter reflects our focus on long-term priorities in a dynamic business environment. The developments in Zambia and Europe mark important milestones in our ongoing journey of becoming a global CDMO."*

Mr. Sandeep Jain, Managing Director, Akums Drugs & Pharmaceuticals Ltd., added: *"CDMO business is navigating through a complex phase, with continued weakening of API prices and sustained flat volumes in the industry. Akums has outpaced industry volume growth. we remain focused on delivering long term shareholder value by further cementing our leadership position in CDMO business, taking measures to grow our domestic and exports branded business and curtailing losses in API and trade generics."*

Highlights are as Follows:

Particulars (Rs Cr)	Q2 FY 26	Q1 FY 26	Q2 FY 25	H1 FY 26	H1 FY 25
Revenue	1,018	1,024	1,033	2,042	2,052
Cost of goods sold	593	582	596	1,174	1192
Employee Cost	189	176	180	365	356
Other Expenses	141	137	136	278	259
Adj EBITDA	94	129	121	223	245
Adj EBITDA Margin	9.3%	12.6%	11.7%	10.9%	12.0%
Adj PAT	43	65	67	107	124
Adj PAT Margin	4.1%	6.2%	6.4%	5.1%	6.0%

### Definitions

- Adjusted EBITDA has been calculated as the sum of profit/ (loss) for the quarter/six months period, tax expenses, finance costs, depreciation and amortization expense, fair value changes to financial instruments, and exceptional items minus other income.
- Adjusted PAT is calculated as the profit for the quarter/six months period plus fair value changes to financial instruments less tax deferred tax created on brought forward losses.
- CDMO: Contract Development and Manufacturing Operations
- API: Active Pharmaceutical Ingredients
- SADC: Southern African Development Community

**For further information, please contact:**

**IR Desk**

Akums Drugs and Pharmaceuticals Ltd

[investors@akums.net](mailto:investors@akums.net)/[ankit.jain@akums.net](mailto:ankit.jain@akums.net)